The previous piece in this series laid out why analyst coverage in healthcare is hard to come by: fewer analysts, a more complex sector, and economic incentives that push research capacity toward the largest names. At full-service investment banks, a filter also favors businesses with investment banking revenue potential. 

Those forces remain in place, and companies still get covered. Some of what decides whether coverage happens sits within a company’s control. 

The stakes explain the effort. Research from the University of Florida found that stocks with no analyst coverage experience a near 5% permanent positive return when coverage is initiated. For a company with a $300 million market cap, that is $15 million in value created without a clinical milestone, a regulatory approval, or any change in the underlying business. It just starts with one analyst covering a name for the first time. 

Invest in building the foundation 

For most small and mid-cap healthcare companies, the path to sell-side attention runs through deliberate, sustained investment in visibility and credibility. 

One route is issuer-paid research, where a company engages an independent research firm to initiate and maintain coverage for a fee. Sophisticated investors understand how it differs from organic sell-side coverage, but it serves a clear purpose. It creates a body of published work that institutional investors can reference, shows that the company’s story merits analysis, and can improve the quality of conversations when management does meet sell-side analysts. 

The other route is a structured investor relations (IR) program that extends beyond quarterly earnings calls, built with specialist advisors who understand how sell-side research decisions are made, how trading liquidity affects them, and how to increase institutional ownership over time. Liquidity matters because analysts will not initiate on names where their clients cannot build meaningful positions, which makes the profile of the shareholder base part of the equation. 

Recent listings face a testing aftermarket. According to Evaluate data, 14 of the 24 US biopharma IPOs this year were trading below their offer price on October 14. 

Make the story easier to tell 

One of the most useful things a company can do is reduce the time it takes an analyst to initiate. An initiation report in healthcare takes four to eight weeks of dedicated work. The analyst builds a financial model, works through the clinical pipeline, assesses probability of technical and regulatory success (PTRS) assumptions, and forms a view on competitive positioning. The faster that groundwork goes, the lower the bar for taking the coverage decision. 

Three factors can compress that ramp time significantly: 

• Clean, consistent financial disclosures 

• Structured pipeline tables 

• Clear segment reporting

Burying relevant data across multiple presentations, changing how key metrics are reported from quarter to quarter, or making clinical timelines hard to extract slows the analyst down at exactly the wrong moment, potentially costing an opportunity for a coverage. 

The material is what a company already publishes, but it is organized so it is useful to someone starting from scratch. Data that sits cleanly in the analytics environments and screening tools analysts use also raises the chance of appearing in the right screens at the right time, including with analysts who are not yet tracking the company. 

Own the ecosystem 

Coverage depends on relationships, and relationships take sustained effort across a broader ecosystem than most IR programs target. Analysts, institutional investors, investment bankers, and conference organizers belong to the same connected system. A company that is consistently accessible, prompt with questions, substantive in investor meetings, and proactive about presenting its story builds something of real commercial value: brand equity in the investment community. 

Every conference presentation, investor meeting, non-deal roadshow, and analyst call is an opportunity to: 

• Increase the number of institutional investors in the shareholder base 

• Build familiarity with the story among potential coverage candidates 

• Demonstrate the management quality that makes analysts comfortable putting their name on an initiation report

Companies that navigate coverage gaps most successfully treat each interaction with the investment community as a brick in a longer-term structure, a relationship that compounds over time. 

This is the third piece in our series on the healthcare coverage gap. Next: why picking up a new name can be an opportunity as well as a cost for analysts, and what an uncovered company can mean for the right research team.